Toll-like receptor 8 (TLR8), a sensor for pathogen-derived single-stranded RNA (ssRNA), binds to uridine (Uri) and ssRNA to induce defense responses. We here show that cytidine (Cyd) with ssRNA also activated TLR8 in peripheral blood leukocytes (PBLs) and a myeloid cell line U937, but not in an embryonic kidney cell line 293T. Cyd deaminase (CDA), an enzyme highly expressed in leukocytes, deaminates Cyd to Uri. CDA expression enabled TLR8 response to Cyd and ssRNA in 293T cells. CDA deficiency and a CDA inhibitor both reduced TLR8 responses to Cyd and ssRNA in U937. The CDA inhibitor also reduced PBL response to Cyd and ssRNA. A Cyd analogue, azacytidine, is used for the therapy of myelodysplastic syndrome and acute myeloid leukemia. Azacytidine with ssRNA induced tumor necrosis factor-α expression in U937 and PBLs in a manner dependent on CDA and TLR8. These results suggest that CDA enables TLR8 activation by Cyd or its analogues with ssRNA through deaminating activity. Nucleoside metabolism might impact TLR8 responses in a variety of situations such as the treatment with nucleoside analogues.
Introduction
Toll-like receptors (TLRs) sense viral and bacterial products including microbial membrane components, flagellin and nucleic acids (NAs) to initiate defense responses (1) . NAs such as double-stranded (ds) RNA, single-stranded (ss) RNA and ssDNA are recognized by TLR3, TLR7/TLR8 and TLR9, respectively (2) . dsRNA and ssDNA directly bind to TLR3 and TLR9, respectively (3) (4) (5) . In contrast, the structures of TLR7 and TLR8 show that these sensors bind to a combination of oligoribonucleotides and nucleosides such as guanosine (Guo) or uridine (Uri), respectively (6, 7) . Functional analyses further show that TLR7 and TLR8 are activated by a combination of ssRNA and nucleosides (8) . These results suggest that nucleosides might impact TLR7 and TLR8 responses in innate immune cells.
Nucleosides are generated by RNA degradation by RNases in lysosomes. In addition to Guo and Uri, adenosine (Ado) and cytidine (Cyd) are generated by RNA degradation. Cyd is deaminated to Uri by Cyd deaminase (CDA) (9) . The role of CDA in the metabolism of Cyd analogues has been extensively studied (10) . A variety of Cyd analogues have been developed as therapeutic agents to control myeloid leukemias and related diseases such as myelodysplastic syndrome. 5-Azacytidine is used in the treatment of myelodysplastic syndrome and acute myeloid leukemia (AML). The toxicity of these drugs is influenced by the activity of CDA (11, 12) , suggesting that these Cyd analogues are rapidly deaminated to Uri analogues in vivo.
We hypothesized that Cyd deamination might enable TLR8 activation by Cyd and ssRNA. We here studied the role of CDA in TLR8 responses. TLR8 in peripheral blood leukocytes (PBLs) and a myeloid leukemia line U937 was activated by Cyd with ssRNA in addition to Uri with ssRNA.
CDA expression was higher in these cells than 293T cells, in which over-expression of CDA enabled a TLR8 response to Cyd and ssRNA. U937 responses to Cyd and ssRNA were impaired by CDA deficiency or a CDA inhibitor. Furthermore, a Cyd analogue 5-azacytidine activated TLR8 in U937 and induced tumor necrosis factor-α (TNF-α) expression in a CDA-dependent manner. These results suggest that CDA expands the nucleoside-sensing window of TLR8 in monocyte/myeloid cells.
Methods

Reagents
U937 cells were cultured in RPMI (Nacalai Tesque) containing 10% Fetal calf serum (FCS), 2 mM l-glutamine (Gibco) and 50 µM 2-mercaptoethanol (2-ME; Nacalai Tesque). Ado, Cyd, Guo and Uri were purchased from MP Biomedicals. Nucleosides from these manufacturers showed similar activity in immune response via TLR8. Pam3CSK4 and R848 were purchased from Invivogen. 5-Azacytidine was purchased from Wako Pure Chemical Industries. SsRNA40 (GsCsCsCsGsUsCsUsGsUsUsGsU sGsUsGsAsCsUsC), in which 's' depicts a phosphorothioate linkage, and the gRNAs (TLR8 gRNA, GCCGTTCTGGTGCTGTACATT; and CDA gRNA, GTATATTGTCATGACGGTCC) were synthesized by FASMAC.
Cell culture and stimulation
U937 cells were plated at a density of 1 × 10 5 cells per well onto 96-well plates and primed with sequential stimulation with 20 ng ml −1 12-O-tetradecanoyl phorbol 13-acetate (PMA) for 24 h, followed by IFN-γ (PeproTech) for 24 h. After the priming with PMA and IFN-γ, cells were stimulated for 24 h with TLR ligands. Human PBLs obtained from healthy subjects were treated with RBC Lysis Buffer (BioLegend), and then seeded at a density of 2 × 10 5 cells per well onto 96-well plates. To inhibit CDA activity, PBLs were pretreated with tetrahydrouridine (THU; Cayman Chemicals) for 6 h before stimulation with TLR ligands. When cells were stimulated by ssRNA40 alone or with nucleosides, the ligands were complexed with 20 μL ml −1 DOTAP transfection reagent (Roche). The supernatant was subjected to ELISA to detect TNF-α (Thermo Fisher Scientific).
Immunoblot analysis of TLR8
U937 cells were lysed by sample buffer containing 50 mM Tris-HCl, 10% glycerol, 1% sodium dodecyl sulfate (SDS) and 10% 2-ME. Cell lysates were sonicated for 15 s and heated at 95°C for 2 min. The samples were separated by SDS-polyacrylamide gel electrophoresis and subjected to immunoblot analysis. Anti-TLR8 mAb (D3Z6J, CST) was diluted (1000×) in a CanGetSignals Solution 1 (Toyobo) and allowed to react with blotted membranes for 16 h. After washing the membrane, proA-HRP diluted (5000×) in CanGetSignals Solution 2 was used to detect TLR8.
Reverse transcription-PCR
RNA purification was conducted with the RNeasy Kit (Qiagen). Single-stranded cDNA was synthesized using ReverTra Ace (TOYOBO). PCR was performed with Tks Gflex DNA polymerase (Takara-Bio). PCR band analysis was performed with MultiNA (Shimazu).
Luciferase assay
293T cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Nacalai Tesque) supplemented with 10% fetal bovine serum, 1× penicillin-streptomycin-glutamine and 50 μM 2-ME. 293T cells were seeded onto collagencoated 24-well plates at a density of 2 × 10 5 cells per well, and transiently transfected with human TLR8 cDNAs in pMXpuro-IRES-rat CD2 (200 ng) and a pNL3.2 NF-κB luc reporter plasmid (1 ng) with polyethylenimine ('Max', MW 40 000). At 20 h after transfection, transfected cells were collected and reseeded onto collagen-coated flat 384-well plates at a density of 1 × 10 4 cells per well to stimulate them with indicated TLR ligands for 6 h. Stimulated cells were subjected to luciferase assay using the Luciferase Assay System (Promega). The relative light unit of chemiluminescence was measured by GloMax Explorer (Promega).
FACS analyses
U937 and human PBL cells were collected and stained with anti-CDA pAb (ab56053, Abcam) followed by anti-rabbit IgG-PE antibody. The Fc receptors on U937 cells were blocked by Human TruStain FcX™ (BioLegend). For membrane permeabilization and fixation, BD Cytofix/Cytoperm™ (BD Bioscience) was used.
Lentiviral transduction for expression of Cas9 and gRNA
To establish mutant cells, the lentiCRISPR v2 vectors (Addgene #52961) encoding gRNAs and cas9 were transfected into the 293FT cells with ViraPower Lentiviral Expression Systems (Thermo Fisher Scientific). After 2 days of incubation, the supernatants were obtained as viral suspensions. After puromycin selection, cells were analyzed without cloning to avoid clonal variation. To perform TLR8 cDNA over-expression, pHIV-zsgreen vector (Addgene #18121) encoding TLR8 cDNA was used.
Human samples
All the experiments using human samples were conducted according to the protocol approved by the Institutional Review Boards at the Institute of Medical Science in the University of Tokyo (#25-72).
Statistical analyses
The t-test was performed by comparing the data. If the P value was <0.05, the difference was judged as significant.
Results and discussion
Synergistic TLR8 activation by Cyd and ssRNA in human myeloid cells
Uri, but not other ribonucleosides, enhanced TLR8 responses to ssRNA in 293T cells (8) . To study TLR8 responses to nucleosides in monocyte/macrophages, TLR8 responses in PBLs were examined. PBLs from two healthy subjects were stimulated with a TLR8 ligand ssRNA40 with a variety of nucleosides.
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In both subjects, Uri, Guo and Cyd significantly enhanced ssRNA-dependent TNF-α production (Fig. 1A) . Although ssRNA40 is known as a TLR8-specific ligand, it remains possible that TLR7 was activated by Guo and ssRNA40. Further study is required to address this issue. We here focused on TLR8 responses to Cyd and ssRNA to study the role of CDA in TLR8 responses. We next used a myeloid leukemia cell line U937. TLR8 cDNA or gRNA targeting TLR8 was expressed in U937 cells. TLR8 expression in these U937 cells was examined by immunoblotting to ensure TLR8 over-expression and TLR8 deficiency (Fig. 1B) . U937 and those expressing TLR8 cDNA (U937-TLR8 cDNA) were stimulated with a variety of TLR8 ligands or a TLR2 ligand Pam3CSK4, and TNF-α production was examined. TNF-α production induced by a TLR8 ligand ssRNA40 at 10 μg ml −1 was increased in U937-TLR8
cDNA cells (Fig. 1C) , indicating that TLR8 responses are augmented by TLR8 over-expression. Additional stimulation with Uri at 1 mM increased TNF-α production in U937 cells. Much higher TNF-α production was detected in U937-TLR8 cDNA cells. In addition to Uri, Cyd at 1 mM showed similar enhancing effects on TNF-α expression in both U937 and U937-TLR8 cDNA. Unexpectedly, a TLR2 ligand Pam3CSK4 weakly but significantly increased TNF-α expression, which might be because weak, ligand-independent TLR8 activation in U937-TLR8 cDNA enhanced TLR2 responses. We next examined U937 expressing gRNA targeting TLR8, U937-TLR8 gRNA. TNF-α production induced by ssRNA40 was impaired in U937-TLR8 gRNA (Fig. 1D) . Previously, we showed that TLR8 is activated by not only Uri but also deoxyuridine (dUri) (8) . Similarly, deoxycytidine (dCyd) may activate ). -, none; A, adenosine; U, uridine; G, guanosine; C, cytidine. The results are represented by average value ± SD from triplicates. (B) Immunoblotting of uncleaved, full-length TLR8 (TLR8F) and β-actin (ACTB) in whole cell lysate from U937, U937 expressing TLR8 cDNA (U937-TLR8 cDNA) or U937 expressing TLR8 gRNA (U937-TLR8 gRNA). (C, D) . TNF-α production by U937, U937-TLR8 cDNA or U937-TLR8 gRNA. These cells were stimulated with nucleoside (1 mM) and ssRNA40 at 10 µg ml −1 or with Pam3CSK4 (P) at 1 μg ml −1 . The results are represented as in (A). *P < 0.05, **P < 0.01, ***P < 0.001.
TLR8. TLR8 gRNA expression abolished TNF-α production induced not only by Uri or dUri with ssRNA40 but also by Cyd or dCyd with ssRNA40. TLR2 responses to Pam3CSK4 were weakly but significantly impaired in U937-TLR8 gRNA for a currently unknown reason. TLR8 might be weakly and homeostatically activated and enhance TLR2 responses. These results suggest that Cyd enhances TLR8 responses to ssRNA40 as much as Uri in PBLs and U937.
CDA is highly expressed in myeloid cells
TLR8 responses in the above immune cells showed sharp contrast to 293T, in which TLR8 does not respond to Cyd and ssRNA (8) . We hypothesized that Cyd to Uri deamination is required for TLR8 activation by Cyd and ssRNA40 in U937 cells. A variety of CDAs are known to mediate Cyd to Uri deamination (13) . Expression of mRNAs encoding APOBEC family members, activation-induced cytidine deaminase (AID), and CDA in U937 and 293T was examined by PCR to seek for a difference between these cells. In U937 cells, CDA, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D and APOBEC3G were expressed ( Fig. 2A ). All these deaminases except APOBEC3C showed higher mRNA expression in U937 than in 293T. CDA deaminates free Cyd and dCyd, whereas APOBEC family members deaminate Cyd and dCyd in RNA and DNA, respectively. We therefore focused on CDA and expression of CDA protein was next examined by flow cytometry analyses. Consistent with PCR analyses, CDA expression in U937 cells was appreciably higher than in 293T cells (Fig. 2B) . TLR8 is expressed in monocytes, macrophages, dendritic cells and neutrophils (14, 15) . Interestingly, CDA is also highly expressed in monocyte/macrophages (16) . Furthermore, treatment with PMA and IFN-γ not only enabled TLR8 responses in U937, but also increases CDA protein expression (16) . Positively correlated expression of mRNAs encoding TLR8 and CDA suggests that CDA might have a role in TLR8 responses in monocyte/macrophages.
CDA enables TLR8 activation by Cyd and ssRNA in 293T cells
Because CDA expression was lower in 293T than U937, poor TLR8 response to Cyd and ssRNA in 293T cells might be ascribed to low CDA expression (8) . CDA was, therefore, transiently expressed in 293T and TLR8 responses to Cyd and ssRNA were studied. Consistent with our expectation, TLR8 responses to ssRNA40 were enhanced by Cyd only when CDA was expressed (Fig. 2C) . Expression of another CDA, APOBEC3G, had no effect on TLR8 response to Cyd and ssRNA40. CDA did not alter the TLR8 response to Uri and ssRNA40. Interestingly, CDA expression also up-regulated the TLR8 response to dCyd and ssRNA, albeit much more weakly than that to Cyd and ssRNA.
To study roles of CDA in TLR8 responses in U937 cells, a gRNA targeting CDA was expressed in U937 cells (U937-CDA gRNA). The lack of CDA expression was ensured by FACS analyses (Fig. 2B) . U937-CDA gRNA was stimulated with a variety of TLR8 ligands and TNF-α expression was measured by ELISA. U937-CDA gRNA cells were impaired in response to Cyd and ssRNA, but not to R848 or Pam3CSK4 (Fig. 3A) . Interestingly, the TLR8 response to Uri and ssRNA was partially but significantly impaired in U937-CDA gRNA. CDA deficiency might alter nucleoside metabolism and thereby partially impair the TLR8 response to Uri and ssRNA40. To obtain another line of evidence for requirement of CDA in the TLR8 response to Cyd and ssRNA40, THU, a Uri analogue competitively inhibiting CDA (17) , was used to treat U937 cells. THU treatment inhibited TNF-α expression by U937 cells stimulated with Cyd and ssRNA40 but not Uri and ssRNA40 (Fig. 3B) . THU treatment also inhibited TNF-α expression in PBLs stimulated with Cyd and ssRNA40 (Fig. 3C) . These results suggest that CDA is required for TLR8 responses to Cyd and ssRNA40.
5-Azacytidine activates TLR8 in a CDA-dependent manner
5-Azacytidine is an inhibitor of DNA methylation and used for the treatment of myelodysplastic syndrome and AML (9, 12). As 5-azacytidine is structurally similar to Cyd (Fig. 4A) , we hypothesized that 5-azacytidine might activate TLR8, after being deaminated by CDA. U937 and U937-TLR8 gRNA cells were stimulated with 5-azacytidine and ssRNA40, and TNF-α expression was studied. Significant TNF-α expression was induced by 5-azacytidine and ssRNA40 in U937 but not U937-TLR8 gRNA (Fig. 4B) , suggesting that 5-azacytidine with ssRNA activates TLR8. To ask whether CDA is required for the TLR8 response to 5-azacytidine and ssRNA40, U937-CDA gRNA cells were examined. TNF-α expression induced by 5-azacytidine and ssRNA40 was significantly decreased in U937-CDA gRNA cells (Fig. 4C ). PBLs were also stimulated with 5-azacytidine and ssRNA40. TNF-α expression was detected in PBLs stimulated with 5-azacytidine at 100 μM and ssRNA40 at 10 μg ml −1 (Fig. 4D) . These responses were inhibited by the CDA inhibitor THU (Fig. 4E) . These results suggest that 5-azacytidine serves as a TLR8 ligand after deamination by CDA.
We here show that TLR8 is activated by Cyd and ssRNA in a manner dependent on CDA-mediated deamination. An embryonic kidney cell line 293T showed lower CDA expression than a myeloid cell line U937 and required CDA expression to respond to Cyd and ssRNA40. Furthermore, TLR8 responses to Cyd and ssRNA40 in U937 cells were inhibited by expression of a gRNA targeting CDA. CDA deficiency decreased the TLR8 response not only to Cyd and ssRNA40, but also to Uri and ssRNA40. The complete lack of CDA might alter nucleoside metabolism and thereby impair the TLR8 response to Uri and ssRNA. The CDA inhibitor THU showed more specific inhibition restricted to the TLR8 response to Cyd and ssRNA40, but not Uri and ssRNA40. These results suggest that CDA is required for TLR8 responses to Cyd and ssRNA.
In our experimental system, we exogenously added nucleosides to activate TLR8. Such alteration in nucleosides occurs in a variety of diseases. Bloom syndrome is an autosomal recessive disorder characterized by marked genetic instability caused by mutations in the BLM gene encoding a RecQ 3′-5′ DNA helicase (18) . In this syndrome, genetic instability . (B, C) U937 cells and PBLs were treated with THU at indicated concentrations for 6 h before stimulation with indicated TLR ligands. TNF-α expression was evaluated as in (A). **P < 0.01, ***P < 0.001. causes pyrimidine pool imbalance, which decreases CDA expression. TLR8 responses might be altered in Bloom syndrome. Pyrimidine pool imbalance may also occur in Fanconi anemia (FA), an inherited disease caused by inactivation of one of a cluster of DNA repair genes called FA complementation group (FANC) genes (19) . Very interestingly, TLR8 responses are enhanced in macrophages lacking one of the FANC genes, FA group C (Fancc) (20) . It is interesting to study CDA expression in Fancc -/-macrophages. These previous studies and our results here suggest that TLR8 responses might be influenced by altered pyrimidine metabolism during DNA damage responses.
TLR8 is activated during human immunodeficiency virus (HIV) infection (21, 22) . Pyrimidine metabolism may also be altered during HIV infection. HIV reverse transcriptase poorly discriminates between dUTP and dTTP, leading to misincorporation of dUTP into DNA (23) . Uracil DNA glycosylase initiates degradation of HIV-1 DNA containing dUTP, up-regulating NA catabolism. Furthermore, the members of the APOBEC family deaminate dCyd in DNA into dUri (24) . Degradation of such edited viral DNA together with CDA-dependent deamination of dCyd and Cyd to dUri and Uri would increase the concentration of dUri and Uri, leading to TLR8 activation during HIV infection. Although DNA degradation during DNA damage responses is thought to occur mainly in the nucleus, nuclear DNA leaks out of the nucleus during DNA damage responses and moves through the autophagy pathway to lysosomes, where nuclear DNA is degraded by lysosomal DNase II (25) . CDA is localized in the cytoplasm and nucleus (26) . Uri and dUri generated by CDA-dependent deamination might traffic through the autophagy pathway to TLR8-containing lysosomes.
Alteration in pyrimidine metabolism may also occur in the treatment with Cyd analogues such as an inhibitor of DNA methylation 5-azacytidine, which is used for the treatment of myelodysplastic syndrome and AML (9, 12) . In addition to inhibiting DNA methylation, our results suggest that 5-azacytidine might act on TLR8 after being deaminated by CDA. TLR8 activation is known to induce differentiation of myeloid leukemia cells (27) . 5-Azacytidine might act on myeloid leukemia cells not only as an inhibitor of DNA methylation, but also as a TLR8 ligand. In this regard, it is interesting to study the responses of TLR8 and TLR7 to a variety of nucleoside analogues, which are now clinically used to control viral infection and leukemias.
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